When the US Centers for Disease Control and Prevention decides whether and how to adopt the adviser's recommendations, it will offer advice on how people should consider the US Food and Drug Administration's permission to use the mix and match approach, formally known as the heterologous approach.
While the advisers just voted to recommend both Moderna and Johnson & Johnson boosters, it will now be up to CDC Director Dr. Rochelle Walensky to accept or modify the committee’s recommendation.
Here's a look at some of the language being considered by the CDC:
The same product that was used for the primary regimen should be used for the booster.
- If that is not available or another product is preferred, heterologous boosting with a single dose of any of the authorized Covid-19 vaccine boosters is acceptable.
Heterologous dosing may be considered for the booster dose only.
- All doses of the primary series and additional dose (if indicated for moderately to severely immunocompromised people who received 2 doses of mRNA vaccine) should utilize the same vaccine product.
Individual benefit-risk assessment may inform which booster product to use.
- Availability of booster product
- Risk profile of vaccine boosters, including rare events